Login / Signup

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.

Pingyu ChenMengjie LuoYanqiu ChenYanlei ZhangChao WangHongchao Li
Published in: Health economics review (2024)
Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.
Keyphrases
  • acute ischemic stroke
  • endothelial cells
  • induced pluripotent stem cells
  • pluripotent stem cells
  • liver failure
  • oxidative stress
  • drug induced
  • aortic dissection